Here are the 10-K annual reports from Sonoma Pharmaceuticals, Inc. (SNOA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SNOA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNOA filings page.
Sonoma Pharmaceuticals’ annual report describes a global specialty medical-device business built on stabilized hypochlorous acid (HOCl) for dermatology, wound care, eye care, podiatry, animal health and surface disinfection. The company sells in over 55 countries, manufactures in Mexico, and emphasizes partnering with distributors rather than building large direct sales forces.
For the year ended March 31, 2026, research and development expenses were $2,271,000, up from $1,814,000 in 2025, as Sonoma advanced new HOCl products and regulatory clearances. About 71% of 2026 revenue came from outside the United States, and customer C represented 15% of net revenues, highlighting both international reach and customer concentration. The company notes significant intercompany loans to its Mexican subsidiary and related tax and withholding exposures, and it operates under extensive U.S., EU and Mexican medical device and healthcare regulations, including 22 FDA 510(k) clearances and updated CE certificates under the EU Medical Devices Regulation.